CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS

Click here to complete the interactive survey.
Submit your responses anonymously to be able to view the aggregate results of the poll.

Catherine is a 30-year-old woman who presents following her first neurological episode. She developed numbness and paraesthesias involving her right leg and lower trunk six weeks ago. Symptoms evolved over several days but remained mild. She continued working throughout the episode and did not require corticosteroid treatment. Her symptoms resolved completely over approximately two weeks. She is otherwise healthy, takes no regular medications and has no history of recurrent or serious infections.

Neurological examination is normal. EDSS is 0. Brain MRI demonstrates six T2/FLAIR lesions typical of MS. There are three periventricular and two juxtacortical white matter lesions and one questionable L optic nerve lesion. There is a question of subtle punctate enhancement of one of the periventricular lesions with gadolinium. There are no infratentorial lesions. Spinal cord MRI is normal. CSF demonstrates CSF-restricted oligoclonal bands. sNfL is normal.

You diagnose her with mild early RRMS. She tells you: “My symptoms were pretty minor and I feel completely normal now.”

Interactive survey

Question 1: Which initial treatment approach would you recommend?

Clinical and MRI monitoring without DMT for now.
Initiate a lower- or moderate-efficacy DMT, with escalation if breakthrough disease occurs.
Initiate a high-efficacy DMT with anti-CD20 therapy.
Either moderate- or high-efficacy therapy is reasonable; I would present both approaches to her and individualize the decision.

Question 2: The patient is concerned that treatment may be disproportionate to her current disease. She says: “If I had severe MS, I could understand using a strong treatment. But everything you’ve told me sounds relatively mild. Why not see how my MS behaves first?” How would you interpret this patient’s apparently mild presentation?

Her favourable features make a lower-efficacy initial treatment reasonable.
Her prognosis is probably favourable, but not sufficiently predictable to exclude high-efficacy treatment.
Her current disease severity should not necessarily determine treatment intensity, because the goal of therapy is prevention of future CNS injury.
High-efficacy treatment should generally be reserved for patients with established markers of aggressive MS.

Question 3: What do you consider the strongest argument for initiating high-efficacy therapy now rather than reserving it for future disease activity?

We cannot reliably identify which apparently mild patients will remain mild.
Early inflammatory CNS injury may be irreversible, making escalation after treatment failure inherently reactive.
High-efficacy therapies provide greater suppression of subclinical MRI disease.
The benefit–risk balance may be most favourable early: inflammatory MS activity is greatest while treatment-related infectious risk is relatively low in young, healthy, minimally disabled patients.
None of these – I would reserve high-efficacy therapy for patients with greater clinical or radiological disease activity.

Question 4: Catherine then adds an important consideration. She says: “My partner and I would like to have children – probably not immediately, but perhaps in the next two or three years. I don’t want an MS treatment to interfere with that.” How does her desire for pregnancy within the next 2–3 years affect your willingness to recommend an anti-CD20 therapy such as ofatumumab?

It makes me substantially less likely to recommend it.
It makes me somewhat less likely to recommend it.
It does not substantially change my recommendation because therapy can be planned around conception.
It may actually favour an anti-CD20 strategy because disease can be strongly suppressed before conception with treatment subsequently adapted around pregnancy.

Question 5: Catherine raises one final concern that reframes the treatment decision: “I’m only 30. If I start suppressing my B cells now, am I going to be doing this for the next 40 years?” Which long-term treatment philosophy best reflects how you would counsel this patient?

Escalation: start with a lower- or moderate-efficacy DMT and reserve high-efficacy DMTs for breakthrough disease.
Continuous high efficacy: start a high-efficacy DMT early and continue while it remains effective and well tolerated.
Front-loaded high efficacy: treat intensively during early MS, with planned reassessment and potential de-escalation as the benefit–risk ratio changes.
I would not adopt a predetermined lifetime strategy; future treatment intensity should depend on her disease activity, treatment tolerance, age, evolving individual risk and the emergence of new data.

NeuroSens

CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS

Related Posts